title: Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.
abstract: We analysed CD56 expression in 70 patients with multiple myeloma (MM) to determine its clinicopathological and prognostic significance. Fifty-five (79%) patients were CD56+. CD56- patients (n = 15) had higher beta2 microglobulin levels and a higher incidence of extramedullary disease, Bence Jones protein, renal insufficiency and thrombocytopenia than CD56+ patients. Their myelomas more frequently had a plasmablastic morphology. Overall survival was significantly lower in CD56- than CD56+ patients (22 vs 63 months, P = 0.0002). We conclude that CD56- MM is a discrete entity associated with more aggressive disease. The higher incidence of plasmablastic cases suggested that CD56- MM may develop from a less mature plasma cell than CD56+ MM.
authors.affiliation: Internal Medicine III, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu-shi, 431-3192 Japan. sahara@hama-med.ac.jp
authors.forename: Naohi
authors.initials: N
authors.lastname: Sahara
authors.forename: Akihiro
authors.initials: A
authors.lastname: Takeshita
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Shigeno
authors.forename: Shinya
authors.initials: S
authors.lastname: Fujisawa
authors.forename: Kaori
authors.initials: K
authors.lastname: Takeshita
authors.forename: Kensuke
authors.initials: K
authors.lastname: Naito
authors.forename: Michio
authors.initials: M
authors.lastname: Ihara
authors.forename: Takaaki
authors.initials: T
authors.lastname: Ono
authors.forename: Sadahiro
authors.initials: S
authors.lastname: Tamashima
authors.forename: Kenji
authors.initials: K
authors.lastname: Nara
authors.forename: Kazunori
authors.initials: K
authors.lastname: Ohnishi
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Ohno
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001536:Bence Jones Protein / Q000032:analysis; D001854:Bone Marrow Cells / Q000276:immunology*; D019002:CD56 Antigen / Q000032:analysis*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology* / Q000401:mortality; D010950:Plasma Cells; D011379:Prognosis; D015996:Survival Rate; D001613:beta 2-Microglobulin / Q000032:analysis
chemical_list: D019002:CD56 Antigen; D001613:beta 2-Microglobulin; D001536:Bence Jones Protein